Manufacturer of Controlled Substances; Notice of Registration, 70986-70987 [E6-20689]

Download as PDF 70986 Federal Register / Vol. 71, No. 235 / Thursday, December 7, 2006 / Notices DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration Importer of Controlled Substances; Notice of Registration By Notice dated July 19, 2006, and published in the Federal Register on July 26, 2006, (71 FR 42417), Lin Zhi International, Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Tetrahydrocannabinols (7370) ..... 3,4–Methylenedioxy-methamphetamine (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (9273) Morphine (9300) ........................... I I II II II II II II sroberts on PROD1PC70 with NOTICES The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lin Zhi International, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 28, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–20693 Filed 12–6–06; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 17:29 Dec 06, 2006 Jkt 211001 Drug By Notice dated July 10, 2006 and published in the Federal Register on July 24, 2006, (71 FR 41837–41838), Lipomed Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ Methaqualone (2565) ................... Gamma hydroxybutyric acid (2010). Lysergic acid diethylamide (7315), 2,5-Dimethoxy-4-(n)propylthiophenethylamine (7438). Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 3,4,5-Trimethoxyamphetamine (7390). 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). 4-Methoxyamphetamine (7411) ... Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. Acetyldihydrocodeine (9051) ........ Dihydromorphine (9145) ............... Heroin (9200) ............................... Normorphine (9313) ..................... Pholcodine (9314) ........................ Tilidine (9750) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Fentanyl (9801) ............................ Sufentanil (9740) .......................... Schedule II II II II II II II II II II II II The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Lipomed Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Lipomed Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: November 28, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–20745 Filed 12–6–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 25, 2006, and published in the Federal Register on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary Street, Baltimore, Maryland 21224, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), E:\FR\FM\07DEN1.SGM 07DEN1 70987 Federal Register / Vol. 71, No. 235 / Thursday, December 7, 2006 / Notices a basic class of controlled substance listed in schedule II. The company plans to manufacture a cocaine derivative to be used in domestic and foreign clinical research studies. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of MGI Pharma to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated MGI Pharma to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: November 28, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–20689 Filed 12–6–06; 8:45 am] BILLING CODE 4410–09–P Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 26, 2006, and published in the Federal Register on August 2, 2006, (71 FR 43814), Orasure Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, Bethlehem, Pennsylvania 18015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: sroberts on PROD1PC70 with NOTICES Schedule Lysergic acid diethylamide (LSD) (7315). 4–Methoxyamphetamine (7411) ... Normorphine (9313) ..................... Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605) .................. Amphetamine (1100) .................... Methamphetamine (1105) ............ Cocaine (9041) ............................. Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... VerDate Aug<31>2005 17:29 Dec 06, 2006 I I I I I II II II II II II Jkt 211001 Schedule Morphine (9300) ........................... Oxycodone (9143) ........................ Meperidine (9230) ........................ Methadone (9250) ........................ Oxymorphone (9652) ................... II II II II II The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Orasure Technologies, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Orasure Technologies, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 28, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–20744 Filed 12–6–06; 8:45 am] DEPARTMENT OF JUSTICE Drug Drug BILLING CODE 4410–09–P DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than February 5, 2007. Dated: November 28, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–20698 Filed 12–6–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated August 7, 2006 and published in the Federal Register on August 15, 2006, (71 FR 46922), Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: Drug DEPARTMENT OF JUSTICE Schedule Manufacturer of Controlled Substances; Notice of Application Coca Leaves (9040) ..................... Raw Opium (9600) ....................... Poppy Straw (9650) ..................... Concentrate of Poppy Straw (9670). Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 20, 2006, Organix Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture a chemical that is a derivative of cocaine that will be sold to their customer for research purposes. Any other such applicant and any person who is presently registered with The company plans to import the listed controlled substances to manufacture bulk controlled substance intermediates for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Penick Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent Drug Enforcement Administration PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\07DEN1.SGM 07DEN1 II II II II

Agencies

[Federal Register Volume 71, Number 235 (Thursday, December 7, 2006)]
[Notices]
[Pages 70986-70987]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20689]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 25, 2006, and published in the Federal 
Register on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary 
Street, Baltimore, Maryland 21224, made application to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Cocaine (9041),

[[Page 70987]]

a basic class of controlled substance listed in schedule II.
    The company plans to manufacture a cocaine derivative to be used in 
domestic and foreign clinical research studies.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
MGI Pharma to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated MGI Pharma to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with State and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substance listed.

    Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-20689 Filed 12-6-06; 8:45 am]
BILLING CODE 4410-09-P